Styrene is an aromatic hydrocarbon best known as an industrial monomer, but it also appears as a minor natural-product volatile in some balsamic materials, including Peru balsam in the AromaForge archive. For this archive the evidence base is strongest for identity, occurrence, metabolism, and toxicology rather than for any beneficial constituent-specific wellness narrative. The profile should therefore stay conservative: styrene is a chemically real balsamic trace constituent with a well-developed hazard literature, not a constituent to frame with therapeutic or skin-benefit claims.
Chemical identity and composition
PubChem identifies styrene as CID 7501 with formula C8H8 and InChIKey PPBRXRYQALVLMV-UHFFFAOYSA-N. PubChem synonym data aligns the major naming set around styrene, vinylbenzene, ethenylbenzene, and phenylethene. In the local archive it appears in Peru balsam at a cited 0.3-1.6%, which supports keeping the record for occurrence context while clearly separating that use context from the much larger occupational toxicology literature.
Aroma and practical use
- Use the recorded sweet, balsamic, plastic-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1994 toxicology review states that the metabolism of styrene to styrene oxide and then to styrene glycol, mandelic acid, and phenylglyoxylic acid is the major pathway of activation and detoxication discussed for humans.
A 1994 toxicology review states that the metabolism of styrene to styrene oxide and then to styrene glycol, mandelic acid, and phenylglyoxylic acid is the major pathway of activation and detoxication discussed for humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2019 critical review concluded that styrene metabolism to styrene oxide can produce DNA adducts and positive in vitro mutagenicity or clastogenicity findings, while styrene or styrene oxide was not supported as clastogenic or aneugenic in vivo in rodents under the reviewed evidence base.
A 2019 critical review concluded that styrene metabolism to styrene oxide can produce DNA adducts and positive in vitro mutagenicity or clastogenicity findings, while styrene or styrene oxide was not supported as clastogenic or aneugenic in vivo in rodents under the reviewed evidence base.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
IARC Volume 121 evaluates styrene as probably carcinogenic to humans and styrene-7,8-oxide as carcinogenic to humans, which is hazard context rather than a consumer-use exposure estimate.
IARC Volume 121 evaluates styrene as probably carcinogenic to humans and styrene-7,8-oxide as carcinogenic to humans, which is hazard context rather than a consumer-use exposure estimate.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
ATSDR's public health statement says the most common health problems in workers exposed to styrene involve the nervous system, including changes in color vision, slowed reaction time, concentration problems, and balance problems.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
IARC's 2019 evaluation makes styrene one of the few AromaForge constituents whose public hazard literature clearly outweighs any plausible benefit-oriented archive narrative.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No archive-ready constituent-specific dermal maximum or cosmetic-benefit study for isolated styrene was verified in this pass, and such positioning would be inappropriate given the hazard profile.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
oxidation to styrene oxide
Review literature identifies oxidation of styrene to styrene oxide, followed by conversion to styrene glycol, mandelic acid, and phenylglyoxylic acid, as the major activation and detoxication pathway discussed for humans.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
dna adduct and in vitro genotoxicity signal via styrene oxide
A modern genotoxicity review concludes that when styrene is metabolized to styrene oxide it can form DNA adducts and yield positive in vitro mutagenicity or clastogenicity results, while in vivo rodent clastogenic or aneugenic results were not supported the same way.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Natural-occurrence sourcing for styrene in balsamic or essential-oil materials is much thinner than the industrial toxicology literature.
- No human clinical benefit literature appropriate for archive use was verified for isolated styrene.
- No constituent-specific cosmetic dermal limit was located in this pass, and the hazard profile argues against benefit-oriented use claims.
- No IFRA, RIFM, Tisserand & Young, or EU Annex III dermal limit or sensitization determination was found for styrene as of 2026-07-13 verification pass; the previous dermal_limit_pct value of 0.1 had no locatable citation and was corrected to null. Styrene's hazard profile (IARC probable human carcinogen) is documented via occupational/systemic toxicology rather than a cosmetic dermal-limit framework.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.